

Ole Haagen Nielsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9389784/publications.pdf>

Version: 2024-02-01

241
papers

14,339
citations

19657

61
h-index

24982

109
g-index

253
all docs

253
docs citations

253
times ranked

16402
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1? generation. <i>Clinical and Experimental Immunology</i> , 2006, 147, 061127015327006-???.	2.6	832
2	Familial Occurrence of Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 1991, 324, 84-88.	27.0	605
3	YAP/TAZ-Dependent Reprogramming of Colonic Epithelium Links ECM Remodeling to Tissue Regeneration. <i>Cell Stem Cell</i> , 2018, 22, 35-49.e7.	11.1	447
4	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1461-1472.	1.3	442
5	Transplantation of Expanded Fetal Intestinal Progenitors Contributes to Colon Regeneration after Injury. <i>Cell Stem Cell</i> , 2013, 13, 734-744.	11.1	329
6	Pregnancy in Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 1983, 18, 735-742.	1.5	288
7	Incidence and Prevalence of Crohn's Disease in the County of Copenhagen, 1962-87: A Sixfold Increase in Incidence. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 609-614.	1.5	282
8	Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2013, 369, 754-762.	27.0	282
9	Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. <i>Pharmacological Research</i> , 2013, 76, 1-8.	7.1	258
10	Incidence and Prevalence of Ulcerative Colitis in Copenhagen County from 1962 to 1987. <i>Scandinavian Journal of Gastroenterology</i> , 1991, 26, 1247-1256.	1.5	252
11	Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management. <i>Annals of Medicine</i> , 2010, 42, 97-114.	3.8	249
12	Clinical Evidence Supporting the Radical Scavenger Mechanism of 5-Aminosalicylic Acid. <i>Gastroenterology</i> , 1990, 98, 1162-1169.	1.3	223
13	Upregulation of Interleukin-12 and -17 in Active Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 180-185.	1.5	222
14	Changes in Extent of Ulcerative Colitis A Study on the Course and Prognostic Factors. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 260-266.	1.5	218
15	Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 71-83.	3.7	218
16	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. <i>Gut</i> , 2001, 49, 42-46.	12.1	212
17	Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. <i>Metabolomics</i> , 2015, 11, 122-133.	3.0	208
18	Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study. <i>PLoS ONE</i> , 2013, 8, e56944.	2.5	182

#	ARTICLE	IF	CITATIONS
19	The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1699-1708.	3.7	179
20	Mitogen activated protein kinases: a role in inflammatory bowel disease?. <i>Clinical and Experimental Immunology</i> , 2009, 158, 272-280.	2.6	147
21	Established and emerging biological activity markers of inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 359-367.	0.4	145
22	Novel Targeted Therapies for Inflammatory Bowel Disease. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 127-142.	8.7	142
23	Metabonomics in Ulcerative Colitis: Diagnostics, Biomarker Identification, And Insight into the Pathophysiology. <i>Journal of Proteome Research</i> , 2010, 9, 954-962.	3.7	141
24	IL-33 is upregulated in colonocytes of ulcerative colitis. <i>Immunology Letters</i> , 2010, 128, 80-85.	2.5	139
25	MAP kinases in inflammatory bowel disease. <i>Clinica Chimica Acta</i> , 2011, 412, 513-520.	1.1	138
26	5-Aminosalicylic Acid in the Treatment of Crohn's Disease: A 16-Week Double-Blind, Placebo-Controlled, Multicentre Study with Pentasa®. <i>Scandinavian Journal of Gastroenterology</i> , 1987, 22, 877-883.	1.5	128
27	Drug Insight: aminosalicylates for the treatment of IBD. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 160-170.	1.7	122
28	Safety of TNF- $\hat{\pm}$ inhibitors during IBD pregnancy: a systematic review. <i>BMC Medicine</i> , 2013, 11, 174.	5.5	117
29	A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn's Disease. <i>PLoS ONE</i> , 2013, 8, e60094.	2.5	117
30	Cytokines and Organ Failure in Acute Pancreatitis. <i>Pancreas</i> , 2012, 41, 271-277.	1.1	114
31	Inflammatory pathways of importance for management of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 64.	3.3	113
32	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. <i>Europace</i> , 2014, 16, 477-484.	1.7	107
33	Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. <i>Clinical Cancer Research</i> , 2002, 8, 156-64.	7.0	107
34	Favourable effect of TNF- $\hat{\pm}$ inhibitor (infliximab) on Blau syndrome in monozygotic twins with adenovoCARD15mutation. <i>Apmis</i> , 2006, 114, 912-919.	2.0	106
35	Diagnosis and management of fistulizing Crohn's disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 92-106.	1.7	104
36	Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome-wide gene expression data. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1032-1038.	1.9	103

#	ARTICLE	IF	CITATIONS
37	Rectal Dialysate and Fecal Concentrations of Neutrophil Gelatinase-Associated Lipocalin, Interleukin-8, and Tumor Necrosis Factor- α in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.4	100
38	ATG16L1: A multifunctional susceptibility factor in Crohn disease. <i>Autophagy</i> , 2015, 11, 585-594.	9.1	100
39	Sulfasalazine Intolerance. <i>Scandinavian Journal of Gastroenterology</i> , 1982, 17, 389-393.	1.5	98
40	Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. <i>Trends in Molecular Medicine</i> , 2014, 20, 652-665.	6.7	96
41	Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. <i>Journal of Medical Virology</i> , 1987, 21, 39-47.	5.0	93
42	The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger. <i>Agents and Actions</i> , 1987, 21, 191-194.	0.7	90
43	Involvement of interleukin-4 and -10 in inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1786-1793.	2.3	90
44	Immune Profiling of Human Gut-Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of Region-Specific Immunity. <i>Immunity</i> , 2020, 52, 557-570.e6.	14.3	90
45	MicroRNAs in inflammatory bowel disease - pathogenesis, diagnostics and therapeutics. <i>World Journal of Gastroenterology</i> , 2012, 18, 4629.	3.3	88
46	Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. <i>Digestive Diseases and Sciences</i> , 1987, 32, 577-582.	2.3	87
47	miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2013, 19, 4289.	3.3	81
48	Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies. <i>Nature Communications</i> , 2018, 9, 1661.	12.8	78
49	Malignant Diseases and Mortality Rate. <i>Scandinavian Journal of Gastroenterology</i> , 1985, 20, 13-18.	1.5	77
50	Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. , 2016, 159, 110-119.		77
51	Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2000, 121, 242-247.	2.6	75
52	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor- α in ulcerative colitis. <i>American Journal of Gastroenterology</i> , 1999, 94, 2923-2928.	0.4	74
53	Clinical Reviews. <i>American Journal of Gastroenterology</i> , 2000, 95, 359-367.	0.4	74
54	Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 395-404.	17.8	73

#	ARTICLE	IF	CITATIONS
55	Cytokines (Immunoinflammatory Hormones) and Their Natural Regulation in Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis): A Review. <i>Digestive Diseases</i> , 1994, 12, 290-304.	1.9	71
56	Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 558-570.	6.9	69
57	Targeting JAK-STAT signal transduction in IBD. , 2018, 192, 100-111.		69
58	Systematic review with meta-analysis: association of vitamin D status with clinical outcomes in adult patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1146-1158.	3.7	69
59	The role of CDX2 in intestinal homeostasis and inflammation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 283-289.	3.8	68
60	IBD medications during pregnancy and lactation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 116-127.	17.8	67
61	Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease. <i>Medicine (United States)</i> , 2015, 94, e963.	1.0	67
62	Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 742-752.	1.3	67
63	COLONIC EXPRESSION AND SYNTHESIS OF INTERLEUKIN 13 AND INTERLEUKIN 15 IN INFLAMMATORY BOWEL DISEASE. <i>Cytokine</i> , 2000, 12, 1531-1536.	3.2	65
64	Onercept for Moderate-to-Severe Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 888-893.	4.4	65
65	Comparative Studies of the Colonic In Situ Expression of Intercellular Adhesion Molecules (ICAM-1, -2). <i>American Journal of Surgical Pathology</i> , 2000, 24, 1115-1124.	0.784314 3.7	64
66	Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 717-722.	3.9	63
67	COX-2/PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis. <i>EBioMedicine</i> , 2018, 36, 497-507.	6.1	63
68	Non-IBD and noninfectious colitis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 28-39.	1.7	61
69	IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis. <i>Journal of Gastroenterology</i> , 2015, 50, 180-190.	5.1	61
70	Interleukin-15 and its role in chronic inflammatory diseases. <i>Inflammation Research</i> , 1998, 47, 285-289.	4.0	60
71	Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1918-1923.	2.3	59
72	Intestinal Interleukin-8 Concentration and Gene Expression in Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1997, 32, 1028-1034.	1.5	59

#	ARTICLE	IF	CITATIONS
73	Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1900-1907.e2.	4.4	59
74	Cytokines in Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1992, 27, 897-906.	1.5	58
75	Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. <i>Liver International</i> , 2018, 38, 532-541.	3.9	58
76	Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease. <i>Trends in Molecular Medicine</i> , 2017, 23, 362-374.	6.7	57
77	Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 74-87.e3.	4.4	57
78	Microscopic colitis: a missed diagnosis?. <i>Lancet, The</i> , 2004, 364, 2055-2057.	13.7	55
79	The safety of osmotically acting cathartics in colonic cleansing. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 557-564.	17.8	55
80	Soluble L-selectin levels predict survival in sepsis. <i>Intensive Care Medicine</i> , 2002, 28, 1613-1618.	8.2	52
81	Steady-State Kinetics of 5-Aminosalicylic Acid and Sulfapyridine during Sulfasalazine Prophylaxis in Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 1986, 21, 693-700.	1.5	51
82	Infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 639-641.	1.6	48
83	Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2018, 12, 923-935.	2.7	48
84	New Strategies for Treatment of Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2014, 1, 3.	2.6	47
85	Systemic Inflammatory Responses during Laparoscopic and Open Inguinal Hernia Repair: A Randomised Prospective Study. <i>The European Journal of Surgery</i> , 2000, 166, 540-544.	0.9	46
86	Gastric Emptying and Subjective Symptoms of Nausea: Lack of Effects of a 5-Hydroxytryptamine-3 Antagonist Ondansetron on Gastric Emptying in Patients with Gastric Stasis Syndrome. <i>Digestion</i> , 1990, 46, 89-96.	2.3	43
87	5-Aminosalicylic Acid in the Treatment of Inflammatory Bowel Disease. <i>Acta Medica Scandinavica</i> , 1987, 221, 227-242.	0.0	43
88	TNF- α -induced down-regulation of CDX2 suppresses MEP1A expression in colitis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 843-851.	3.8	43
89	Rational Management of Iron-Deficiency Anaemia in Inflammatory Bowel Disease. <i>Nutrients</i> , 2018, 10, 82.	4.1	43
90	Prognostic factors in neuroblastomas treated in denmark from 1943 to 1980:A statistical estimate of prognosis based on 253 cases. <i>Cancer</i> , 1986, 58, 2726-2735.	4.1	42

#	ARTICLE	IF	CITATIONS
91	Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2016, 55, 257-274.	3.5	42
92	Managing vitamin D deficiency in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2019, 10, 394-400.	1.8	42
93	Telomere dysfunction activates YAP1 to drive tissue inflammation. <i>Nature Communications</i> , 2020, 11, 4766.	12.8	42
94	Tuft Cells and Their Role in Intestinal Diseases. <i>Frontiers in Immunology</i> , 2022, 13, 822867.	4.8	42
95	Gastric emptying rate and small bowel transit time in patients with irritable bowel syndrome determined with ^{99m} Tc-labeled pellets and scintigraphy. <i>Digestive Diseases and Sciences</i> , 1986, 31, 1287-1291.	2.3	41
96	Activation of neutrophil Chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1987, 47, 605-611.	1.2	41
97	Genome-wide gene expression analysis of mucosal colonic biopsies and isolated colonocytes suggests a continuous inflammatory state in the lamina propria of patients with quiescent ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 999-1007.	1.9	41
98	Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1780-1785.	2.3	39
99	Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet-derived 1 alpha in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 454-463.	1.5	39
100	Enhanced capacity for release of leukotriene B4 by neutrophils in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1987, 46, 501-505.	0.9	38
101	Expression of E-selectin, sialyl Lewis X, and macrophage inflammatory protein-1alpha by colonic epithelial cells in ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1998, 43, 596-608.	2.3	38
102	A role for interleukin-33 in TH2-polarized intestinal inflammation?. <i>Mucosal Immunology</i> , 2011, 4, 496-502.	6.0	38
103	Recent Advances Using Immunomodulators for Inflammatory Bowel Disease. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 575-588.	2.0	37
104	Rotavirus Antibodies in the Mother and Her Breast-Fed Infant. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1985, 4, 414-420.	1.8	35
105	Use of biological molecules in the treatment of inflammatory bowel disease. <i>Journal of Internal Medicine</i> , 2011, 270, 15-28.	6.0	34
106	Collagenous sprue: a coeliac disease look-alike with different treatment strategy. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014203721-bcr2014203721.	0.5	34
107	Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. <i>BMC Medicine</i> , 2017, 15, 184.	5.5	34
108	Mucosal vitamin D signaling in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102672.	5.8	34

#	ARTICLE	IF	CITATIONS
109	SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. <i>Science Signaling</i> , 2020, 13, .	3.6	34
110	The Incidence of Anemia, Hypoproteinemia, and Edema in Infants as Presenting Symptoms of Cystic Fibrosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1982, 1, 355-360.	1.8	32
111	Technology Insight: metabonomics in gastroenterology—basic principles and potential clinical applications. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 332-343.	1.7	32
112	Use of thiopurines in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 1040.	3.3	32
113	Involvement of CDX2 in the cross talk between TNF- α and Wnt signaling pathway in the colon cancer cell line Caco-2. <i>Carcinogenesis</i> , 2014, 35, 1185-1192.	2.8	31
114	Influence of Smoking on Colonic Gene Expression Profile in Crohn's Disease. <i>PLoS ONE</i> , 2009, 4, e6210.	2.5	30
115	Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 27-33.	3.7	29
116	Incidence of, phenotypes of and survival from small bowel cancer in Denmark, 1994–2010: a population-based study. <i>Journal of Gastroenterology</i> , 2016, 51, 891-899.	5.1	29
117	Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. <i>BMJ Open Gastroenterology</i> , 2018, 5, e000208.	2.7	29
118	Simple and efficient method for isolation and cultivation of endoscopically obtained human colonocytes. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, G1122-G1128.	3.4	29
119	Tissue-regenerating functions of coagulation factor XIII. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 806-816.	3.8	28
120	Identification, isolation and analysis of human gut-associated lymphoid tissues. <i>Nature Protocols</i> , 2021, 16, 2051-2067.	12.0	28
121	Telomere dysfunction instigates inflammation in inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28
122	CARD15 Single Nucleotide Polymorphisms 8, 12 and 13 Are Not Increased in Ethnic Danes with Sarcoidosis. <i>Respiration</i> , 2007, 74, 76-79.	2.6	27
123	Transcriptional Analysis of Left-sided Colitis, Pancolitis, and Ulcerative Colitis-associated Dysplasia. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2340-2352.	1.9	27
124	The role and advances of immunomodulator therapy for inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 177-189.	3.0	27
125	Expression profiling of apoptosis-related genes in enterocytes isolated from patients with ulcerative colitis. <i>Apmsis</i> , 2006, 114, 508-517.	2.0	26
126	Epithelial apoptosis: Cause or consequence of ulcerative colitis?. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 1429-1434.	1.5	26

#	ARTICLE	IF	CITATIONS
127	Muramyl dipeptide responsive pathways in Crohn's disease: from NOD2 and beyond. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 3391-3404.	5.4	26
128	Modulation of Gut Microbiota in Pathological States. <i>Engineering</i> , 2017, 3, 83-89.	6.7	26
129	How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. <i>Genetics in Medicine</i> , 2017, 19, 133-143.	2.4	26
130	Neuroblastomas treated at the four major child oncologic clinics in Denmark 1943-1980: An evaluation of 180 cases. <i>Medical and Pediatric Oncology</i> , 1985, 13, 180-186.	1.0	25
131	The Circulating Common Gamma Chain (CD132) in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 1998, 93, 323-328.	0.4	25
132	Interleukin-4 and 13 Induce the Expression and Release of Monocyte Chemoattractant Protein 1, Interleukin-6 and Stem Cell Factor From Human Detrusor Smooth Muscle Cells: Synergy With Interleukin-1 β and Tumor Necrosis Factor- α . <i>Journal of Urology</i> , 2006, 175, 760-765.	0.4	25
133	Mucosal Healing in Ulcerative Colitis. <i>Advances in Clinical Chemistry</i> , 2013, 59, 101-123.	3.7	25
134	pcaGoPromoter - An R Package for Biological and Regulatory Interpretation of Principal Components in Genome-Wide Gene Expression Data. <i>PLoS ONE</i> , 2012, 7, e32394.	2.5	25
135	Integration of transcriptomics and metabolomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. <i>Metabolomics</i> , 2014, 10, 280-290.	3.0	24
136	A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. <i>Nutrients</i> , 2017, 9, 499.	4.1	24
137	Calcium Absorption and Acceptance of Low-Lactose Milk Among Children with Primary Lactase Deficiency. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1984, 3, 219-223.	1.8	23
138	Arachidonic acid metabolism in human neutrophils: Lack of effect of cyclosporine A. <i>International Journal of Immunopharmacology</i> , 1986, 8, 419-426.	1.1	23
139	Continuous cytokine exposure of colonic epithelial cells induces DNA damage. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 363-369.	1.6	23
140	The management of iron deficiency in inflammatory bowel disease - an online tool developed by the RAND/UCLA appropriateness method. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1109-1118.	3.7	23
141	Proximal collagenous gastroenteritides: Clinical management. A systematic review. <i>Annals of Medicine</i> , 2014, 46, 311-317.	3.8	23
142	Will novel oral formulations change the management of inflammatory bowel disease?. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 709-718.	4.1	23
143	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <i>EClinicalMedicine</i> , 2020, 20, 100271.	7.1	23
144	Effect of Rebamipide on Acetic Acid-induced Gastric Ulcer in Rats: Involvement of Hepatocyte Growth Factor. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 141-146.	1.5	22

#	ARTICLE	IF	CITATIONS
145	Involvement of oxygen-derived free radicals in the pathogenesis of chronic inflammatory bowel disease. <i>Klinische Wochenschrift</i> , 1991, 69, 995-1000.	0.6	21
146	Alpha-Defensin DEFA1A3 Gene Copy Number Elevation in Danish Crohn's Disease Patients. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3517-3524.	2.3	21
147	Effect of 5-Aminosalicylic Acid and Analogous Substances on Superoxide Generation and Intracellular Free Calcium in Human Neutrophilic Granulocytes. <i>Scandinavian Journal of Gastroenterology</i> , 1993, 28, 527-532.	1.5	20
148	Subcellular Localization of Intercellular Adhesion Molecule-1 in Colonic Mucosa in Ulcerative Colitis. <i>Ultrastructural Pathology</i> , 2002, 26, 113-121.	0.9	20
149	Upregulation of cIAP2 in regenerating colonocytes in ulcerative colitis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 1031-1038.	2.8	20
150	ERK controls epithelial cell death receptor signalling and cellular FLICE-like inhibitory protein (c-FLIP) in ulcerative colitis. <i>Journal of Molecular Medicine</i> , 2013, 91, 839-849.	3.9	20
151	Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2046.	4.1	20
152	Increased hepatic urea synthesis in patients with active inflammatory bowel disease. <i>Journal of Hepatology</i> , 1996, 24, 587-593.	3.7	19
153	Circulating L-selectin levels and endothelial CD34 expression in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 1998, 93, 1854-1859.	0.4	19
154	Colonic epithelial cell expression of ICAM-1 relates to loss of surface continuity: A comparative study of inflammatory bowel disease and colonic neoplasms. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 318-325.	1.5	19
155	Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF- α Independent Crohn Disease. <i>Medicine (United States)</i> , 2016, 95, e3417.	1.0	19
156	Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer. <i>Microorganisms</i> , 2022, 10, 1371.	3.6	19
157	Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol phosphate formation in L-M and arachidonic acid release in 3T3 cells. <i>Cellular Signalling</i> , 1990, 2, 479-487.	3.6	18
158	Attenuated apoptosis response to Fas-ligand in active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1623-1629.	1.9	18
159	Assessment of the validity of a multigene analysis in the diagnostics of inflammatory bowel disease. <i>Journal of Internal Medicine</i> , 2014, 275, 484-493.	6.0	18
160	Prognosis After First-Time Myocardial Infarction in Patients With Inflammatory Bowel Disease According to Disease Activity. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 857-862.	2.2	18
161	Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants. <i>Clinical and Experimental Immunology</i> , 2015, 179, 426-434.	2.6	18
162	Cellular inhibitor of apoptosis protein 2 controls human colonic epithelial restitution, migration, and Rac1 activation. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G92-G99.	3.4	18

#	ARTICLE	IF	CITATIONS
163	Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 415-423.	2.3	17
164	Evidence for Impaired CARD15 Signalling in Crohn's Disease without Disease Linked Variants. <i>PLoS ONE</i> , 2009, 4, e7794.	2.5	17
165	Alpha-1 Antitrypsin and Granulocyte Colony-stimulating Factor as Serum Biomarkers of Disease Severity in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1077-1088.	1.9	17
166	Impact of T300A Variant of ATG16L1 on Antibacterial Response, Risk of Culture Positive Infections, and Clinical Course of Crohn's Disease. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e122.	2.5	17
167	Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2021, 116, 243-253.	0.4	17
168	LFA-1 subunit expression in ulcerative colitis patients. <i>Digestive Diseases and Sciences</i> , 1996, 41, 670-676.	2.3	16
169	Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1023-1031.	3.7	16
170	Alcohol modulates circulating levels of interleukin-6 and monocyte chemoattractant protein-1 in chronic pancreatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 277-282.	1.5	16
171	Clinical phenotype and gene expression profile in Crohn's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G298-G304.	3.4	16
172	IBD metabolomics predicts phenotype, disease course, and treatment response. <i>EBioMedicine</i> , 2021, 71, 103551.	6.1	16
173	A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue. <i>Biomaterials</i> , 2020, 262, 120248.	11.4	16
174	Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 243-248.	1.6	15
175	Impact of feedback and monitoring on colonoscopy withdrawal times and polyp detection rates. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000142.	2.7	15
176	Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. <i>BMJ Open</i> , 2018, 8, e018166.	1.9	15
177	Serum Concentration and Chemotactic Activity of E-selectin (CD62E) in Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 1994, 3, 215-218.	3.0	14
178	Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1995, 9, 75-79.	3.7	14
179	Ex vivo intestinal adhesion of Escherichia coli LF82 in Crohn's disease. <i>Microbial Pathogenesis</i> , 2011, 51, 426-431.	2.9	14
180	Normal Cultivable Microflora in Upper Jejunal Fluid in Children Without Gastrointestinal Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1984, 3, 683-686.	1.8	13

#	ARTICLE	IF	CITATIONS
181	Soluble interleukin-2 receptors in ulcerative colitis. <i>Mediators of Inflammation</i> , 1993, 2, 115-118.	3.0	13
182	Interleukin-2 receptor $\hat{1}\pm$ and $\hat{1}^2$ chain expression by circulating $\hat{1}\pm\hat{1}^2$ and $\hat{1}^3\hat{1}^4$ T cells in inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 1995, 40, 291-295.	2.3	13
183	Expression of ICAM-1 in colon epithelial cells: an ultrastructural study performed on in vivo and in vitro models. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 774-781.	2.8	13
184	Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2561-2562.	27.0	13
185	Integrative Transcriptomic and Metabonomic Molecular Profiling of Colonic Mucosal Biopsies Indicates a Unique Molecular Phenotype for Ulcerative Colitis. <i>Journal of Proteome Research</i> , 2015, 14, 479-490.	3.7	13
186	Iron replacement therapy. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 128-135.	2.3	13
187	Comparison of an Open and a Closed Tube System for Collection of Jejunal Juice. <i>Scandinavian Journal of Gastroenterology</i> , 1983, 18, 353-357.	1.5	12
188	Continuous interferon- γ or tumor necrosis factor- γ exposure of enterocytes attenuates cell death responses. <i>Cytokine</i> , 2004, 27, 113-119.	3.2	12
189	Identification of TNF- \hat{A} -Responsive Promoters and Enhancers in the Intestinal Epithelial Cell Model Caco-2. <i>DNA Research</i> , 2014, 21, 569-583.	3.4	12
190	Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. <i>Journal of Gastroenterology</i> , 2016, 51, 796-807.	5.1	11
191	Fluorescence-based tracing of transplanted intestinal epithelial cells using confocal laser endomicroscopy. <i>Stem Cell Research and Therapy</i> , 2019, 10, 148.	5.5	11
192	Activation of neutrophil Chemotaxis by leukotriene B4 and 5-hydroxyeicosatetraenoic acid in chronic inflammatory bowel disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1987, 47, 605-611.	1.2	11
193	Serum interferon activity in inflammatory bowel disease. <i>Inflammation</i> , 1988, 12, 169-179.	3.8	10
194	Adhesion Molecules in Inflammatory and Neoplastic Intestinal Diseases. <i>Digestive Diseases</i> , 1995, 13, 322-336.	1.9	10
195	Impaired Sensitivity to $\hat{1}^2$ Integrin-Blocking in ICAM-1-Mediated Neutrophil Migration in Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 621-629.	1.5	10
196	CARD15 Status and Familial Predisposition for Crohn's Disease and Colonic Gene Expression. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1783-1789.	2.3	10
197	Objective Quantification of Immune Cell Infiltrates and Epidermal Proliferation in Psoriatic Skin: A Comparison of Digital Image Analysis and Manual Counting. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 453-458.	1.2	10
198	Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 424-436.	8.7	10

#	ARTICLE	IF	CITATIONS
199	Microarrays and Crohn's disease: Collecting reliable information. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 369-377.	1.5	9
200	Treatment response and colonic gene expression in patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 834-840.	1.5	9
201	Biological Treatment of Crohn's Disease. <i>Digestive Diseases</i> , 2012, 30, 121-133.	1.9	9
202	Can TNF inhibitors be administered during the third trimester?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 130-131.	17.8	9
203	Tube for Sampling of Uncontaminated Small-Bowel Juice. <i>Scandinavian Journal of Gastroenterology</i> , 1983, 18, 359-363.	1.5	8
204	A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 1775-1779.	2.3	8
205	Quantification of specific <i>E. coli</i> in gut mucosa from Crohn's disease patients. <i>Journal of Microbiological Methods</i> , 2011, 86, 111-114.	1.6	8
206	Regulation of Laminin β 2 Expression by CDX2 in Colonic Epithelial Cells Is Impaired During Active Inflammation. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 298-307.	2.6	8
207	Expression of 5-lipoxygenase mRNA is unchanged in the colon of patients with active inflammatory bowel disease. <i>Inflammation Research</i> , 2002, 51, 423-426.	4.0	7
208	Spontaneous aggregation of leukocytes in active ulcerative colitis might be ICAM-1 dependent. <i>Inflammation Research</i> , 2004, 53, 458-461.	4.0	7
209	Insulin-like Growth Factor Binding Protein 3 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 780-784.	2.3	7
210	Are NOD2 polymorphisms linked to a specific disease endophenotype of Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2392-2401.	1.9	7
211	Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels. <i>Npj Genomic Medicine</i> , 2017, 2, 3.	3.8	7
212	Same review quality in open versus blinded peer review in "Ugeskrift for Læger". <i>Danish Medical Journal</i> , 2012, 59, A4479.	0.5	7
213	Concentrations of IgA, Secretory IgA, IgM, Secretory IgM, IgD, and IgG in the Upper Jejunum of Children Without Gastrointestinal Disorders. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1988, 7, 867-871.	1.8	6
214	Arachidonic acid and calcium metabolism in melittin stimulated neutrophils. <i>Mediators of Inflammation</i> , 1992, 1, 313-317.	3.0	6
215	Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 743-744.	3.7	6
216	Which Biological Agents Are Most Appropriate for Ulcerative Colitis?. <i>Annals of Internal Medicine</i> , 2014, 160, 733.	3.9	6

#	ARTICLE	IF	CITATIONS
217	Methotrexate for inflammatory bowel disease: time for reconsideration. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 407-409.	3.0	6
218	Molecular Manipulations and Intestinal Stem Cell-Derived Organoids in Inflammatory Bowel Disease. <i>Stem Cells</i> , 2022, 40, 447-457.	3.2	6
219	Ca ²⁺ response in neutrophils after exposure to bacterial N-formyl-methionyl-leucyl-phenylalanine. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 267-273.	1.6	5
220	Lipidomic Trajectories Characterize Delayed Mucosal Wound Healing in Quiescent Ulcerative Colitis and Identify Potential Novel Therapeutic Targets. <i>International Journal of Biological Sciences</i> , 2022, 18, 1813-1828.	6.4	5
221	Arachidonic Acid Metabolism in Neutrophil Granulocytes Obtained from Synovial Fluid in Rheumatoid Arthritis. <i>Scandinavian Journal of Rheumatology</i> , 1990, 19, 387-391.	1.1	4
222	Comparative Studies of Superoxide Production by Microbial Wall Product-Primed Neutrophils in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2004, 49, 878-882.	2.3	4
223	Metabonomics in Gastroenterology and Hepatology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3638.	4.1	4
224	Effects of antirheumatic drugs on endogenous arachidonate metabolism and chemotaxis in human neutrophil granulocytes. <i>Agents and Actions</i> , 1989, 26, 233-234.	0.7	3
225	In vitro Superoxide Production by Peripheral Neutrophils from Patients with Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 1994, 3, 161-164.	3.0	3
226	Expression of common gamma chain on peripheral blood mononuclear cells in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 1997, 42, 372-377.	2.3	3
227	Caspase 14 does not influence intestinal epithelial cell differentiation. <i>Cell Death and Differentiation</i> , 2013, 20, 524-524.	11.2	3
228	An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas. <i>International Journal of Colorectal Disease</i> , 2017, 32, 509-512.	2.2	3
229	Biosimilars for Management of Crohn Disease. <i>Annals of Internal Medicine</i> , 2019, 170, 129.	3.9	3
230	Serum from NSAID-treated patients attenuates the capacity of rat leukocytes to synthesize leukotriene B ₄ . <i>Inflammation Research</i> , 1996, 45, 31-34.	4.0	2
231	ADRENOGENITAL SYNDROME AND CYSTIC FIBROSIS. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1982, 71, 339-341.	1.5	1
232	Pediatric Tube System for Collection of Uncontaminated Jejunal Juice. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1983, 2, 483-486.	1.8	1
233	Section Review: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: The immunological network: Novel approaches to the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 1996, 5, 555-564.	4.1	1
234	W1568 Inhibitor of Apoptosis Protein-2 (cIAP2) Is Important for Colonic Epithelial Wound Healing. <i>Gastroenterology</i> , 2009, 136, A-693.	1.3	1

#	ARTICLE	IF	CITATIONS
235	Anti-TNF-a Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease. <i>Frontiers of Gastrointestinal Research</i> , 0, , 206-213.	0.1	1
236	Chemotactic properties of ICAM-1 and PECAM-1 on neutrophils in ulcerative colitis: Influence of prednisolone. <i>Gastroenterology</i> , 2000, 118, A354.	1.3	0
237	Overexpression of Receptors for Insulin and Epidermal Growth Factor in Dysplastic Inflamed Colonic Mucosa Correlates With Increased Cancer Risk in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2011, 140, S-350.	1.3	0
238	Anti-Inflammatory Effects of Smac-Mimetic BV6 on Immune Cells in Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S764.	1.3	0
239	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	0
240	Involvement of cellular inhibitor of apoptosis protein 2 (cIAP2) in intestinal wound healing. <i>FASEB Journal</i> , 2011, 25, 121.1.	0.5	0
241	Recent therapeutic advances in inflammatory bowel disease. <i>IDrugs: the Investigational Drugs Journal</i> , 2002, 5, 618-22.	0.7	0